Key Points {#FPar1}
==========

Our meta-analysis of randomized controlled trials (RCTs) without any concomitant pharmacological osteoarthritis (OA) treatments permitted during the trials did not identify any safety issue associated with intra-articular hyaluronic acid (IAHA); however, the certainty of this new evidence was graded between "low" and "moderate".A shortcoming in the reporting of harms-related data in manuscripts communicating outcomes of RCTs with IAHA in OA was the reason for this uncertainty, which does not allow for a definitive conclusion regarding the safety of IAHA.Additional studies are required to further investigate the safety profile of IAHA, particularly any association with serious adverse events and long-term safety; moreover, authors of studies on IAHA are encouraged to report in a transparent way all harms data collected from RCTs in the future.

Introduction {#Sec1}
============

Osteoarthritis (OA) is a chronic disorder, affecting joints such as hand, knee and hip, that causes considerable pain, increasing disability, and progressive cartilage degeneration \[[@CR1]\]. OA occurs frequently in adults aged over 50 years and is a major cause of disability worldwide \[[@CR2], [@CR3]\]. The incidence of OA is rising due to the aging population and the increase in obesity \[[@CR1]\]. OA has a complex pathophysiology that is incompletely understood. There is no established disease-modifying therapy for OA as yet, and hence the treatment of OA relies on a combination of pharmacological and non-pharmacological therapies that can manage the symptoms of OA, primarily pain and loss of function \[[@CR4]\]. In practice, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are widely prescribed to relieve pain and improve joint function, and yet have significant toxicity \[[@CR5]--[@CR8]\]. Analgesics and NSAIDs are particularly poorly tolerated by OA patients \[[@CR9], [@CR10]\], who are frequently of advanced age, with comorbidities and are receiving polypharmacy. Intra-articular (IA) injections of corticosteroids, such as triamcinolone hexacetonide and methylprednisolone acetate, are also often prescribed. However, systemic absorption occurs following IA corticosteroid injection, which can lead to systemic adverse events (AEs), and precautions should be observed in patients with concomitant diseases, such as hypertension and diabetes mellitus \[[@CR11]--[@CR13]\].

Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic AEs associated with IA corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions \[[@CR14], [@CR15]\]. IAHA is demonstrated to have a positive effect on pain and joint function \[[@CR16]\]. A network meta-analysis comparing the effectiveness of pharmacological interventions for knee OA found IAHA to be the most efficacious treatment, with an effect size (ES) of 0.63 on pain (95% credible interval \[CrI\] 0.39--0.88). IA placebo itself had an ES of 0.29 (95% CrI 0.04--0.54); nonetheless a statistically significant effect for IAHA was found at 3 months (ES = 0.34, 95% CrI 0.26--0.42) \[[@CR17]\]. IAHA is also demonstrated to have a longer lasting effect on pain and function compared with IA corticosteroids, lasting up to 6 months \[[@CR18], [@CR19]\].

There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including reduction in concomitant analgesia use, and delay in the need for total knee replacement surgery \[[@CR20]--[@CR22]\]. However, despite evidence attesting to the efficacy of IAHA injections, particularly for knee OA, and the widespread use of IAHA in clinical practice, controversy still persists regarding the relative risk:benefit of IAHA, largely due to mixed reports on the safety of IAHA. Consequently, there is a lack of agreement among national and international guidelines regarding the use of IAHA for the medical management of symptomatic knee OA \[[@CR4], [@CR23]--[@CR29]\].

Eight meta-analyses of RCTs comparing IAHA to IA placebo have evaluated the safety of IAHA \[[@CR16], [@CR17], [@CR30]--[@CR35]\]. A Cochrane review of 76 RCTs was unable to conclude a definitive comment on the safety of the hyaluronic acid (HA) class of products due to sample-size restrictions; however, no major safety issues were detected, and in some analyses, IAHA demonstrated similar efficacy to systemic forms of active intervention, with more local reactions but fewer systemic AEs \[[@CR16]\]. Recent meta-analyses on the safety of different IAHA products have found that HA is generally well-tolerated, with a low incidence of AEs and without risk for serious adverse events (SAEs) \[[@CR35]--[@CR37]\]. However, a meta-analysis published in 2012 raised concerns regarding the safety of IAHA, finding an increased risk of SAEs associated with IAHA compared with sham or non-intervention control (relative risk = 1.41, 95% confidence interval \[CI\] 1.02--1.97) \[[@CR33]\]. Notably, almost all of those previous meta-analyses which have assessed the safety of IAHA used only published data, and it is well known that safety data are under-reported in manuscripts. Additionally, the concomitant use of oral NSAIDs during some clinical trials was not taken into account in the previous analyses. The objective of this study was therefore to reassess the safety of HA injections in the management of OA in a systematic review and meta-analysis of randomized, placebo-controlled trials (RCTs). In order to better estimate the safety profile of IAHA in OA, authors of the manuscripts and/or sponsors of studies were contacted to get the full report of AEs.

Methods {#Sec200}
=======

The protocol of this systematic review and meta-analysis has been previously registered in the PROSPERO database (registration number: CRD42017071906). The systematic review was performed in accordance with the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CR38]\]. The findings were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR39]\]. All the review process (study selection and risk of bias assessment) was undertaken using Covidence, the Cochrane platform for systematic reviews.

Eligibility Criteria {#Sec3}
--------------------

Randomized, double-blind, placebo-controlled, parallel-group trials which have assessed AEs associated with IAHA in patients with OA were eligible for inclusion in this meta-analysis. The following studies were excluded: cross-over studies, reviews or meta-analyses, letters, comments or editorials. Studies that allowed concomitant anti-OA medications during the trial (other than rescue medication such as paracetamol or aspirin) were also excluded for the main meta-analysis, but were kept and used for a parallel analysis.

Data Sources and Search Strategies {#Sec4}
----------------------------------

A comprehensive literature search was undertaken in the databases MEDLINE (via Ovid), Cochrane Central Register of Controlled Trials (Ovid CENTRAL) and Scopus. Each database was searched from inception up until 19 June 2017. We searched for RCTs of IAHA in OA, using a combination of study design-, treatment-, and disease-specific key words and/or Medical Subject Heading (MeSH) terms. While AEs were the outcomes of interest for this study, we decided to avoid the outcome-specific key words in the search strategies because of the possibility that a study on the efficacy of a drug may have not mentioned terms related to AEs in its title, abstract or in the keywords sections. The search was limited to English and French publications and to human subjects. Detailed search strategies for MEDLINE/CENTRAL and Scopus databases are reported in the Electronic Supplementary Material (ESM1).

Two clinical trial registries, ClinicalTrials.gov (<http://clinicaltrials.gov/>) and the World Health Organization's International Clinical Trials Registry Platform Search portal (<http://apps.who.int/trialsearch/>), were also checked for trial results that would not have been published. Finally, very recent meta-analyses were also screened for any additional relevant studies. For all studies that met the selection criteria, authors of the manuscripts and/or sponsors of studies were automatically contacted to get the full report of AEs, as far as there was any way to contact them (email, fax, telephone number or co-author email in another article).

We set up search alerts in the bibliographic databases for any new relevant RCTs that were published from 19 June 2017 until 30 September 2018.

Study Selection and Data Extraction {#Sec5}
-----------------------------------

Two members of the review team (GH and XR) independently evaluated each title and abstract to exclude only obvious irrelevant studies, according to the predefined eligibility criteria. At this step, the criteria related to adverse effects were not considered for selection, as studies focusing on the efficacy of a treatment may not report data about adverse effects in the abstract; this means that all trials mentioning only the efficacy information were retrieved at this step. After this first step, the two investigators independently reviewed the full texts of the articles not excluded during the initial screening stage to determine whether the studies met all selection criteria. Those which did not meet these criteria were definitely excluded. All differences of opinion regarding the selection of articles were resolved through discussion and consensus between the two investigators (GH and XR); any persistent disagreement was solved with the intervention of another member of the review team (AG or VR). A flowchart with the number of included studies at each step was established, including the reasons for excluding studies during the full-text reading process.

The full texts of the selected studies were screened for extraction of relevant data, using a standard data extraction form. Outcome results data were independently extracted by two investigators of the review team (GH and XR). For each study, the following data were extracted: characteristics of the manuscript, characteristics of the trial, objective and design of the study, characteristics of the patients, characteristics of the disease, characteristics of the treatments, AEs (outcomes) reported during the trial, and the main conclusion of the study. The raw data (number of events in each arm of the study) were extracted for each outcome. The number of patients who experienced at least once any body system related AE (e.g. nervous system, gastrointestinal system) as well as specific AEs within each body system (e.g. headache, abdominal pain) were extracted. The total number of patients who experienced at least once any AE during the trial and the total number of patients who withdrew from the trial due to AEs were also extracted. Intention-to-treat data were only used when reported or supplied by the study authors or sponsor.

Assessment of Risk of Bias in Included Studies {#Sec6}
----------------------------------------------

Two members of the review team (GH and XR) independently assessed the risk of bias in each study, using the Cochrane Collaboration's tool for risk of bias assessment \[[@CR38]\]. The following characteristics were evaluated:Random sequence generation: we assessed whether the allocation sequence was adequately generated.Allocation concealment: we assessed the method used to conceal the allocation sequence, evaluating whether the intervention allocation could have been foreseen in advance.Blinding of participants and personnel: we assessed the method used to blind study participants and personnel from knowledge of which intervention a participant received and whether the intended blinding was effective.Blinding of outcome assessment: we assessed the method used to blind outcome assessors from knowledge of which intervention a participant received and whether the intended blinding was effective.Incomplete outcome data: we assessed whether participants exclusions, attrition and incomplete outcome data were adequately addressed in the paper.Selective outcomes reporting: we checked whether there was evidence of selective reporting of AEs.

Each of these items was either categorized as "low risk of bias", "high risk of bias", or "unclear risk of bias". "Low risk of bias" or "high risk of bias" was attributed for an item when there was sufficient information in the manuscript to judge the risk of bias as "low" or "high"; otherwise, "unclear risk of bias" was attributed to the item. Disagreements were solved by discussion between the two reviewers (GH and XR) during a consensus meeting and involved, when necessary, another member of the review team for final decision (AG or VR).

Outcomes of Interest {#Sec7}
--------------------

The main System Organ Classes (SOCs) that are likely to be affected by the use of IAHA in the treatment of OA were explored in this meta-analysis. The primary outcomes of interest were MedDRA (Medical Dictionary for Regulatory Activities) SOC-related AEs: gastrointestinal disorders, cardiac disorders, vascular disorders, respiratory, thoracic and mediastinal disorders, nervous system disorders, skin and subcutaneous tissue disorders, musculoskeletal and connective tissue disorders, renal and urinary disorders, infections and infestations, as well as hypersensitivity reaction, and overall severe AEs and SAEs. Secondary outcomes were withdrawals due to AEs (i.e. the number of participants who stopped the treatment due to an AE) and total number of AEs (i.e. the number of patients who experienced any AE at least once).

Data Analysis {#Sec8}
-------------

Analyses were performed using STATA 14.2 software. We described harms associated with the treatment as odds ratio (OR) with 95% CI. We computed an overall ES for each primary or secondary outcome (AE). Anticipating substantial variability among trial results (i.e. the inter-study variability), we assumed heterogeneity in the occurrence of the AEs; thus, we planned to use random-effects models for the meta-analyses. We estimated the overall effects and heterogeneity using the DerSimonian and Laird random-effects model \[[@CR40]\]. As this method provides a biased estimate of the between-study variance with sparse events \[[@CR41], [@CR42]\], we also performed the meta-analyses using the restricted maximum likelihood (REML) method \[[@CR43]\]. Indeed, we planned in the protocol to use specific methods for rare events analysis, in case it would be necessary. However, we reported only the results from the DerSimonian and Laird random-effects model, as we found no difference in the effects computed by the two methods. We preferred reporting the results from the DerSimonian and Laird method (which uses a correction factor), because it allows for displaying studies with null event on the forest plot, even if those with null event in both the intervention and control groups are excluded from the overall ES computation. On the contrary, with the REML method, these studies are not displayed on the forest plot. Additionally, the STATA command which performs the meta-analysis based on the REML method (metaan) does not have any option for displaying subgroups on the same graphic, in contrary to the DerSimonian and Laird method command (metan), which has this option ("by").

We tested heterogeneity using the Cochran's Q test. As we are performing a random-effects meta-analysis, we used the Tau-squared (Tau^2^) estimate as the measure of the between-study variance. The *I*-squared (*I*^2^) statistic was used to quantify heterogeneity, measuring the percentage of total variation across studies due to heterogeneity \[[@CR44]\]. In the case of substantial heterogeneity (*I*^2^ \> 50%) \[[@CR45]\], we pre-specified to undertake subgroup analyses, stratifying the analyses according to the following: participants' age in the intervention group, duration of OA complaint, type of joint treated (knee, hip), number of joints treated, origin of the HA used (avian, microbial), molecular weight of HA (high weight versus low weight), molecular structure of HA (cross-linked versus non-cross-linked), HA manufacturer, dosing regimen, number of cycles, number of injection per cycle (single versus repeated), follow-up duration, type of sham intervention used (saline versus other), use of anaesthetic before injection, ultrasound guidance for injection, industry involvement (sponsored versus non-sponsored), risk of bias in the studies (e.g. studies with low risk of bias versus all other studies).

We assessed evidence for publication bias by visual inspection of funnel plots and using the Harbord's test for funnel plot asymmetry \[[@CR46]\], which is more suitable for dichotomous outcomes with ESs measured as OR \[[@CR47]\] than the classical Egger's test \[[@CR48]\]. The quality of each evidence was assessed using the GRADE approach \[[@CR49]\], and a summary of findings table was prepared using the GRADEpro online software \[[@CR50]\].

Additional Analysis {#Sec9}
-------------------

We performed additional post hoc meta-analyses, in parallel with the main meta-analysis including the studies responding to our pre-defined eligibility criteria. Indeed, studies allowing concomitant anti-OA medications, as excluded based on our eligibility criteria, as well as all studies with or without concomitant anti-OA medications, were considered separately in parallel to the primary meta-analysis. These parallel analyses were done based on the same principles announced in the data analysis section of this manuscript for the main meta-analysis. However, instead of depicting the results of the parallel analyses in separate forest plots, we preferred showing all the analyses for each outcome on the same figure, to allow for an easy comparison. Therefore, considering the rationale of this safety meta-analysis (the exclusion of studies with other anti-OA medication allowed), the parallel analyses on one single forest plot are not to be considered as subgroup analyses, as for a classical meta-analysis.

Results {#Sec10}
=======

Initial Study Selection and Characteristics {#Sec11}
-------------------------------------------

Database searches initially identified 1481 records, from which, after exclusions, 88 articles were assessed for eligibility. Of these, 67 studies were excluded for various reasons (Fig. [1](#Fig1){ref-type="fig"}). Twenty-two papers were included in the qualitative synthesis, according to our pre-specified selection criteria, and only nine studies having adequate data were ultimately included in the meta-analysis \[[@CR51]--[@CR72]\]. These studies responding to our selection criteria were without any concomitant pharmacological OA therapy, in accordance with the review protocol. Indeed, since this is a meta-analysis on the safety of IAHA, we could not include trials that had allowed another pharmacological OA treatment as concomitant medication (other than rescue medication such as paracetamol or aspirin).Fig. 1Flow chart of the study. *OA* osteoarthritis

Table [1](#Tab1){ref-type="table"} presents the characteristics of the studies included through the systematic review process (those included in the quantitative synthesis---meta-analysis---are highlighted). Almost all these studies involved patients with knee OA; only three were on patients with other joint OA (ankle OA). Most of the trials had follow-up durations varying between 25 and 29 weeks; only one trial had a follow-up duration of at least 52 weeks. Single or repeated injections of HA during a single cycle were reported, respectively, by four and 17 studies; one study was a multiple-arm study with single and repeated injections (one, three or five injections). Avian derivative or microbial derivative HA was used, but in the majority of the articles, the origin of the compound was not specified.Table 1Characteristics of the studies included from the systematic review process, according to the pre-specified selection criteria (without concomitant OA treatment; those studies ultimately included in the meta-analysis are highlighted in bold type)StudyLocation of OATreated groups/age of participants (mean ± SD or median \[P25--P75\])Origin of HAMolecular weightDoseNumber of cycles/number of injections per cycleFollow-up duration (weeks)Data provided in the article (type of AE/% of patients considered)Published data usable for M-A? (yes/no)Full data provided by the author/sponsor? (source of information)**Altman 1998** \[[@CR51]\]KneeIA HA: 62 ± 10\
IA SA: 65 ± 10Avian sodium hyaluronate500--730 kDa2 mL (20 mg) HA in saline vehicle1/526 weeksMost commonly occurring AEs (\> 5%) on all randomized patientsYesNo (Fidia Pharma)**Altman 2004** \[[@CR52]\]KneeIA HA: Mean: 62.9 Range : 41--85\
IA SA: Mean: 63.3 Range: 35--85Streptococci \[Non-animal stabilized hyaluronic acid (NASHA)\]NA3 mL injection : 60 mg HA in buffered sodium chloride, 0.9%1/126 weeksSummary according to the relationship of AEs to the treatment. *Data for TRAEs (the most common) and serious AEs*YesNo (Author)Arden 2014 \[[@CR53]\]KneeIA HA: 64.5 (29--84)\
IA SA: 60.9 (30--86)NANA60 mg, single IA injection1/16 weeksTRAEs/SummaryNoNo (Author)**Baltzer 2009** \[[@CR54]\]KneeIA HA: 57.4 ± 12.0\
IA SA: 60.3 ± 10.7NA1.4 x 10^6^ Da2 mL of HA (1% solution of HA)1/329 weeksResults mainly presented as percentages and numbers of patients with 'mild', 'moderate', 'severe' AEs. *Frequencies reported for some SOCs*YesAuthor contacted with no response**Brandt 2001** \[[@CR55]\]KneeIA HA: 65 ± 8.4\
IA SA: 67 ± 8.4Avian (Rooster combs)1.0--2.9 million Da2 mL (15 mg/mL)1/327 weeksAEs reported by ≥ 5 % of the patients (by Body System)YesAuthor contacted with no responseCarrabba 1995 \[[@CR56]\]KneeIA HA 1 injection: 61.3 ± 6.8\
IA HA 3 injections: 60.0 ± 7.1\
IA HA 5 injections: 60.6 ± 7.9\
IA Placebo: 60.0 ± 7.0Avian (Rooster combs)500--730 kDa20 mg/2 mL, 1, 3 or 5 injections1/1, 3 or 526 weeksSummary; focus on local AEs.NoNo contact information foundCohen 2008 \[[@CR57]\]AnkleIA HA: 56.2 ± 15.1\
IA SA: 43.4 ± 14.9NA500--730 kDaNA (2 mL HYL)1/526 weeksSummary/Not detailedNoAuthor contacted with no responseDeCaria 2012 \[[@CR58]\]KneeIA HA: 71.93 ± 6.83\
IA inert HA (Placebo): 72.93 ± 5.48NA730 kDa2ml of 20 mg/ml HA1/326 weeksSummary/Not detailed.NoAuthor contacted with no responseDeGroot 2012 \[[@CR59]\]AnkleIA HA: 54.1 ± 14.5\
IA SA: 61.9 ± 14.1Avian derivate (derived from rooster combs)620,000 to 1,170,000 DaEach 2.5 mL of Supartz contains 25 mg of sodium hyaluronate1/112 weeksSummary/Not detailedNoAuthor contacted with no responseDiracoglu 2009 \[[@CR60]\]KneeIA HA: 59.4 ± 9.9\
IA SA: 56.2 ± 7.2NANANA1/3NA (Short-term study. 'Injections were repeated in both groups three times after every one-week')Summary/Not detailedNoAuthor contacted with no response**Dixon 1988** \[[@CR61]\]KneeIA HA and IA SA: Mean: 68.5 Range: 43--85NANA20 mg sodium hyaluronate (2 mL)1/1148 weeksTreatment related or possibly related AEs reported.YesNo (Fidia Pharma)Gormeli 2017 \[[@CR62]\]KneeIA HA: 53.5 ± 14\
IA SA: 52.8 ± 12.8NANA ('A high molecular weight HA')2 mL (30 mg/ 2 mL HA)1/326 weeksAEs assessed, but results not reportedNoAuthor contacted with no responseHangody 2017 \[[@CR63]\]KneeIA HA: 59.2 ± 8.6\
IA SA: 58.0 ± 9.0NANA4 mL, 88 mg HA1/126 weeksSummary: numbers of AEs reported, not frequenciesNoYes, data sent by the author as "Number of AEs - By Severity" and not frequencies; not adequate for M-AHuang 2011 \[[@CR64]\]KneeIA HA: 65.9 ± 8.1\
IA SA: 64.2 ± 8.4Avian (naturally derived from rooster combs)500--730 kDa20 mg HA /2 mL1/525 weeksSummary/Not detailed. Number of SAEs reported, not frequenciesNoNo (Fidia Pharma)**Jorgensen 2010** \[[@CR65]\]KneeIA HA: 62.6 ± 11.4\
IA SA: 61.4 ± 11.1NANA2 ml Hyalgan (10 mg/ml)1/513 weeks to a maximum of 52 weeks after the 1st injectionSummary/Not detailed. Per group numbers of AEs reportedNoYes (Author)Karlsson 2002 \[[@CR66]\]KneeIA HA (Artzal): 72 ± 7\
IA HA (Synvisc): 70 ± 7\
IA SA: 71 ± 6NAArtzal : \~10^6^ Da\
Synvisc : \~7 x 10^6^ DaArtzal: 2.5 ml (1% HA);\
Synvisc : 2.0 ml (0.8% HA)1/352 weeksSummary/Not detailed. Number of AEs reported, not the frequencies of specific AEsNoNo (Author)Kotevoglu 2006 \[[@CR67]\]KneeIA HA (Orthovisc) : 58.6 ± 8.0\
IA HA (Synvisc) : 59.7 ± 8.0\
IA SA : 60.1±5.4NANA\
(Orthovisc: Low molecular weight\
Synvisc: High molecular weight)NA1/326 weeksSummary/Not detailedNoAuthor contacted with no responseKul-Panza 2010 \[[@CR68]\]KneeIA HA: 59.5 ± 8.8\
IA SA: 62.8 ± 7.8NA1.5 million Da (average)2 mL 1.5% (15 mg/mL) of intra-articular HA1/9 (3 injections a week, for 3 consecutive weeks).14 weeksSummary/Not detailedNoClarifications from the author not sufficient for inclusion of this study in the M-APetrella 2002 \[[@CR69]\]KneeIA HA (+ Placebo tablet): 67.3 ± 8.9\
IA SA (+ Placebo tablet): 62.6 ± 9.5NA (Suplasyn)NA2ml, 10mg/ml1/312 weeksSummary/Not detailedNoAuthor contacted with no response**Puhl 1993** \[[@CR70]\]KneeIA HA: 62.1 (41--75)\
IA SA: 60.8 (40--74)Avian (Rooster combs)6.0--12.0 × 10^5^ Da25 mg of sodium hyaluronate/ 2.5 ml1/518 weeksAll AEs seem to have been reported (treatment-related and others)YesNo contact information found**Salk 2006** \[[@CR71]\]AnkleIA HA: 57.8 ± 14.7\
IA SA: 60.0 ± 13.9NA500--730 kDa1 mL of hyaluronic acid (10 mg/mL)1/526 weeksDetailed report of AEs: *usable for analysis*YesAuthor contacted with no response**Van der Weegen 2015** \[[@CR72]\]KneeIA HA: 58.7 ± 9.6\
IA SA: 60.1 ± 10.1Produced from the bacterium *Streptococcus equi* by a process of continuous fermentation.2.2 M Da1.5 % HA (30 mg/2 ml)1/329 weeksSummary/Not detailedNoYes (Author)Where published data were adequate for inclusion in the M-A and a full safety report was also provided by the author/sponsor, we preferentially used the full data obtained from the author/sponsor*AE* adverse event, *HA* hyaluronic acid, *IA* intra-articular, *IAHA* intra-articular hyaluronic acid, *IASA* intra-articular saline, *M*-*A* meta-analysis, *NA* not available (i.e. information not provided in the manuscript), *OA* osteoarthritis, *SAE* serious adverse event, *SOC* System Organ Class, *TRAEs* treatment-related adverse events

Of the 22 articles selected for inclusion, only seven had their published data usable for the meta-analysis; thus, the risk of selective outcome reporting was found to be "high" in more than 75% of the retrieved studies. Full safety data were received for only two studies (Table [1](#Tab1){ref-type="table"}). Figures [2](#Fig2){ref-type="fig"}a and [3](#Fig3){ref-type="fig"}a include a summary of the risk of bias assessed for each study included in the qualitative synthesis and the risk of bias items presented as percentages across all these studies.Fig. 2**a** Risk of bias summary in studies without concomitant pharmacological OA treatment (studies meeting the pre-specified selection criteria): review authors' judgements about each risk of bias item for each study included in the primary qualitative synthesis. **b** Risk of bias summary in studies with concomitant pharmacological OA treatment (studies included in the parallel qualitative synthesis): review authors' judgements about each risk of bias item for each study included in the parallel qualitative synthesis. *OA* osteoarthritisFig. 3**a** Risk of bias graph for studies without concomitant pharmacological OA treatment: review authors' judgements about each risk of bias item presented as percentages across all studies included in the primary qualitative synthesis. **b** Risk of bias graph for studies with concomitant pharmacological OA treatment: review authors' judgements about each risk of bias item presented as percentages across all studies included in the parallel qualitative synthesis. *OA* osteoarthritis

Post Hoc Study Selection and Characteristics {#Sec12}
--------------------------------------------

From the 67 studies previously excluded according to the protocol, 21 with other pharmacological OA treatments permitted were "a posteriori" included in a parallel qualitative synthesis (Fig. [1](#Fig1){ref-type="fig"}), from which eight studies with adequate data were ultimately included in a parallel meta-analysis \[[@CR73]--[@CR93]\]. In most of these studies, oral NSAIDs were permitted as rescue or concomitant medication; in a few others, opiates and steroids were allowed.

This "post hoc" decision to consider these studies with other pharmacological OA treatments in a parallel analysis was made because we were surprised by their number when compared to the number of studies without any concomitant pharmacological OA treatment allowed. We sought by so doing to compare the results from these two groups of studies, knowing that our main conclusions regarding the safety profile of IAHA will primarily be based on the results of the analyses using the studies without any concomitant pharmacological OA treatment (those responding to our pre-specified selection criteria).

Table [2](#Tab2){ref-type="table"} presents the characteristics of the studies included in the parallel qualitative synthesis (those included in the meta-analysis are highlighted). The majority of the studies retrieved for this parallel qualitative synthesis included patients with knee OA, as for the studies without any concomitant anti-OA medication; three studies included patients with hip OA, one studied patients with hand OA, and two others each included patients with OA of the glenohumeral joint and the first metatarsophalangeal joint. For most of the studies, the follow-up durations were ≤ 26 weeks; three studies had follow-up durations of 52 weeks and one of 174 weeks.Table 2Characteristics of studies included in the parallel qualitative synthesis (trials with concomitant OA treatment allowed; those studies ultimately included in the parallel meta-analysis are highlighted in bold type)StudyLocation of OATreated groups/Age of participants (mean ± SD or median \[P25--P75\])Origin of HAMolecular weightDoseNumber of cycles/number of injections per cycleFollow-up duration (weeks)Concomitant OA treatment (medication) allowedData provided in the article (type of AE/% of patients considered)Published data usable for M-A? (yes/no)Full data provided by the author/sponsor? (source of information)**Altman 2009** \[[@CR73]\]KneeIA HA: 62,5 ± 11\
IA SA: 60,8 ± 10Derived from nonpyogenic *Streptococcus zooepidemicus* (biologic fermentation)2.4--3.6 Million Da20mg/2ml of 1% solution hyaluronate1/326 weeksNon-prescription nutraceuticals (e.g., glucosamine, chondroitin), topical analgesics, and nasal or inhaled corticosteroidsReport mainly focused on Musculoskeletal and Connective Tissue AEs. Any, Withdrawals, Severe and serious AEs also reported. No detail for othersYesAuthor contacted with no responseAtchia 2011 \[[@CR74]\]HipIA HA: 69 ± 9\
IA SA: 70 ± 10NA (Non-animal stabilized HA, Durolane)NA (a high molecular weight hyaluronan)3ml/60mg1/18 weeksThere were no restrictions regarding medication useSummary/Not detailedNoYes, data sent by the author as number of AEs, and not frequencies; not adequate for M-A.Chevalier 2010 \[[@CR75]\]KneeIA HA: 63.6 ± 9.64\
IA SA: 62.5 ± 9.17NA \[Hylan G-F 20 (Synvisc)\]6000 kDa (Average)NA (6 ml intra-articular injection)1/126 weeksAnalgesics/ NSAIDs (with a half-life of 5 h or less for indications other than osteoarthritis pain)Report focused on target knee AEsNoNo (Author)Day 2004 \[[@CR76]\]Knee*Mean (Range)*\
IA HA: 62 (39-79)\
IA Placebo vehicle: 62 (33-75)Avian (extracted from rooster combs)6.2 × 10^5^ to 11.7 × 10^5^ Da25 mg of sodium HA in 2.5 ml of phosphate buffered saline1/517 weeksIn the results section: Important Codeine compounds and NSAID use in violation of the protocol, but patients not excludedSummary/Not detailedNoNo (Author)**Dougados 1993** \[[@CR77]\]KneeIA HA: 67 ± 9.7\
IA Vehicle placebo: 69.0 ± 10.6Avian (extracted from cock's combs)500-730 kDaHyalectin 20 mg (10 mg/ml)1/452 weeksAny nonsteroidal anti-inflammatory drugs (NSAIDs) and/or analgesicsAll AEs seem to have been reportedYesAuthor contacted with no responseHenderson 1994 \[[@CR78]\]Knee*Data for severity group 2.*\
IA HA: 72.1 ± 1.7\
IA Vehicle: 67.0 ± 1.7Avian (extracted from rooster combs)500,000 -750,000 Da20 mg Hyalgan in 2 ml of sterile buffered saline1/522 weeksAlternative analgesia or anti-inflammatory treatment (permitted during the follow up but not during the treatment period)Summary/Not detailedNoNo contact information foundHenrotin 2017 \[[@CR79]\]KneeIA HA: 66.9 ± 10.4\
IA SA: 63.0 ± 8.9NA (Kartilage^®^ Cross, a new reticulated HA supplemented with mannitol)NA2.2ml, 16mg/ml HA1/126 weeksNSAIDs, Topical NSAIDsSummary of numbers of AEsNoNo (Laboratories VIVACY, France. Data promised but not provided.)**Heyworth 2008** \[[@CR80]\]Hand (Basal joint - thumb)IA HA: 65.0 ± 2.0\
IA SA: 64.0 ± 2.0Avian (derived from rooster combs)NANA (1-mL injection of hylan G-F 20)1/226 weeksNSAIDs (ibuprofen 400 mg every 4--6 h, as needed)All reported: "No AE observed during the study"YesAuthor contacted with no responseHuskisson 1999 \[[@CR81]\]KneeIA HA: 65.8 ± 8.8\
IA SA: 64.8 ± 9.3Avian (extracted from rooster combs)500--730 kDa20mg/2ml1/526 weeksNSAIDsSummary focusing in local reactions (in the majority of patients); *specific reactions reported*NoNo contact information found**Jubb 2003** \[[@CR82]\]KneeIA HA: 63.5 ± 9.5\
IA SA: 65.0 ± 9.1NA (Hyalgan^®^)500--730 kDa20mg/2ml HA3/352 weeksFree use of analgesics and NSAIDs except indomethacinMost common AEs (≥ 5%) reported. *Only Specific AEs reported (SOC ranking was possible for some AEs)*YesNo (Fidia Pharma)**Kwon 2013** \[[@CR83]\]Glenohumeral joint (shoulder)IA HA: 66.1 ± 10.7\
IA SA: 66.1 ± 11.7Avian (extracted from rooster combs)620,000--1,170,000 DaNA1/326 weeksCurrent regimen of pain medications could be maintained but no additional treatment to the shoulderReport mainly focused on device related AEs. AEs by SOC not reported, but *"Any" and "Serious" AEs reported*YesAuthor contacted with no responseLohmander 1996 \[[@CR84]\]KneeIA HA: 58.53 ± 8.34\
IA SA: 58.03 ± 8.44NA (Hyaluronan, Artzal^®^)1000 kDa (Average)25mg/2.5ml1/520 weeksSimple analgesics, in addition to NSAIDsSummary/Not detailedNoNo (Author)**Lundsgaard 2008** \[[@CR85]\]KneeIA HA: 68.8 ± 6.27\
IA SA: 69.6 ± 7.27NA (Hyaluronate, Hyalgan^®^)NA2ml of Hyalgan, 10.3 mg/ml1/426 weeksNSAID (inclusive COX-2 selective inhibitors), codeine, and tramadolNo AE (serious, non-serious, local reaction, post injection 'flares') reported during the trial. But 1 withdrawal after 2 weeks due to cerebral haemorrhageYesAuthor contacted with no responseMunteanu 2011 \[[@CR86]\]First MTPJ (foot)IA HA: 53.7 ± 11.3\
IA SA: 55.3 ± 11.2NA (Hylan G-F 20, Synvisc)NANA (up to 1 ml of hylan G-F 20)1/1 (with an option of a 2nd and final injection at month 1 or 3 if there was no improvement)26 weeksNot clear: "Use of (paracetamol rescue medication) and co-interventions to relieve first MTPJ pain, as secondary outcome"Summary/Not detailedNoAuthor contacted with no responseNavarro-Sarabia 2011 \[[@CR87]\]KneeIA HA: 63.0 ± 8.2\
IA SA: 63.9 ± 8.9Obtained from strains of *Streptococcus zoopidemicus*900,000 Da (Average)2.5 ml 1% sodium hyaluronate4/5174 weeksShort cycles of NSAIDNumbers of AEs reported, not per SOC frequenciesNoAuthor contacted with no responsePetrella 2008 \[[@CR88]\]KneeIA HA, DMW: 68.0 ± 6.0\
IA HA, LMW: 69.0 ± 5.0\
IA HA, HMW: 71.0 ± 9.0\
IA SA: 71 ± 8NADMW: 580--780 kDa + 1.2 to 2.0 million Da\
LMW: 500--730 kDa\
HMW: 6 million DaNA1/316 weeksAnalgesics (including NSAIDs)Summary/Not detailedNoAuthor contacted with no response**Pham 2004** \[[@CR89]\]KneeIA HA: 64.9 ± 8.4\
IA SA: 64.9 ± 7.7Produced from *Streptococcus equus*1.900 kDa25 mg of sodium hyaluronate in 2.5 ml3/352 weeksNSAIDsMost commonly seen AEs reported. By SOC report for some SOCs, and only specific AEs for GIYesAuthor contacted with no responseQvistgaard 2006 \[[@CR90]\]HipIA HA: 65.0 ± 14.0\
IA SA: 64.0 ± 11.0NA (Hyalgan^®^)NANA\
(2 ml HA)1/313 weeksUsual analgesic consumption (with no other information)Summary/Not detailedNoNo (Fidia Pharma)Richette 2009 \[[@CR91]\]HipIA HA: 60.8 ± 10.2\
IA SA: 59.5 ± 12.6Obtained from *Streptococcus* fermentation900,000 DaNA (2.5 ml of HA)1/113 weeksNSAIDs or step 2 analgesicsSummary: All AEs not reported. Some specific (probably related to treatment) AEs reportedNoNo (Author)**Strand 2012** \[[@CR92]\]KneeIA HA: 60.9 ± 10.24\
IA SA: 60.3 ± 9.97Avian (Chicken combs)NA30 mg HA in 3 ml1/113 weeksNSAIDs, herbal therapies, oral HA, glucosamine, chondroitin sulfate, minocycline and short-acting oral opiatesFocus on TRAEs: per SOC results nor reported; "*Any" and "Serious" AEs frequencies provided.*YesAuthor contacted with no responseWobig 1998 \[[@CR93]\]KneeIA HA: 60.0 ± 2.0\
IA SA: 64.0 ± 2.0NA (Hylan G-F 20)NANA (2 ml of Hylan G-F 20)1/326 weeksSteroids, NSAIDs, analgesics, or any other therapy for the treatment of OASummary/Not detailedNoNo contact information foundWhere published data were adequate for inclusion in the M-A and a full safety report was also provided by the author/sponsor, we preferentially used the full data obtained from the author/sponsor*AE* adverse event, *COX-2* cyclooxygenase 2, *DMW* dual molecular weight, *GI* gastrointestinal, *HA* hyaluronic acid, *HMW* high molecular weight, *IA* intra-articular, *IAHA* intra-articular hyaluronic acid, *IASA* intra-articular saline, *LMW* low molecular weight, *M*-*A* meta-analysis, *MTPJ* metatarsophalangeal joint, *NA* not available (i.e. information not provided in the manuscript), *NSAID* non-steroidal anti-inflammatory drug, *OA* osteoarthritis, *P25--P75* 25th percentile--75th percentile, *SD* standard deviation, *SOC* System

From the 21 studies included in the parallel qualitative synthesis (i.e. with concomitant anti-OA medication), only eight, with data partially reported, were included in the parallel quantitative synthesis (meta-analysis); for the others, the published data were not usable for the meta-analysis and no adequate data were obtained from the study authors or sponsors. A "high" risk of selective outcome reporting bias was found in the majority of the studies. Figures [2](#Fig2){ref-type="fig"}b and [3](#Fig3){ref-type="fig"}b include a summary of the risk of bias assessed for each study included in the parallel qualitative synthesis and the risk of bias items presented as percentages across all these studies.

Primary Outcomes {#Sec13}
----------------

Using the available data, IAHA was found to be associated with significantly lower odds of infections and infestations, overall (OR = 0.61, 95% CI 0.40--0.93; *I*^2^ = 0%) and in studies without any concomitant anti-OA medication allowed (OR = 0.49, 95% CI 0.27--0.89; *I*^2^ = 0%) (Fig. [4](#Fig4){ref-type="fig"}). A reduced odds of infections was also found with studies that allowed concomitant OA treatment, but this did not reach statistical significance (OR = 0.76, 95% CI 0.42--1.38). For this outcome, two main studies accounted for more than 96% of the weight in the overall analysis. Influenza, urinary tract infection and pneumonia were the most reported specific events in the placebo group, and these specific events were reported by only one study, for which the authors shared the full safety report with us [@CR65]\].Fig. 4Forest plot displaying the results of the meta-analyses comparing infections and infestations with IAHA versus placebo in patients with OA: analysis on studies without concomitant anti-OA medication allowed, analysis on studies with concomitant anti-OA medication allowed, and overall analysis. *CI* confidence interval, *IAHA* intra-articular hyaluronic acid, *OA* osteoarthritis

No statistically significant difference was found between IAHA treatment and placebo for all other types of disorders, including gastrointestinal, cardiac, vascular, respiratory, thoracic and mediastinal, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue, renal and urinary system disorders, and hypersensitivity reaction (see the Electronic Supplementary Material, ESM2).

There were significant increased odds of reporting SAEs in the IAHA group, both overall (OR = 1.78, 95% CI 1.21--2.63; *I*^2^ = 0%) and in studies that allowed concomitant OA treatment (OR = 1.78, 95% CI 1.10--2.89; *I*^2^ = 0%) (Fig. [5](#Fig5){ref-type="fig"}). An increased odds of SAEs was also found in studies without concomitant anti-OA treatment, but this did not reach statistical significance (OR = 1.78, 95% CI 0.92--3.47; *I*^2^ = 0%). No statistically significant difference was found between IAHA treatment and placebo for severe AEs.Fig. 5Forest plot displaying the results of the meta-analyses comparing serious adverse events with intra-articular hyaluronic acid versus placebo in patients with OA: overall analysis and analyses on studies with and without concomitant anti-OA medication allowed. *CI* confidence interval, *OA* osteoarthritis

Secondary Outcomes {#Sec14}
------------------

Overall, there were no more total AEs reported with IAHA versus placebo (OR = 1.09, 95% CI 0.90--1.31; *I*^2^ = 17.7%) and specifically without concomitant OA treatment allowed (OR = 1.19, 95% CI 0.92--1.54; *I*^2^ = 0%) and with concomitant OA treatment (OR = 1.04, 95% CI 0.77--1.40; *I*^2^ = 0%) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot displaying the results of the meta-analyses comparing total adverse events with intra-articular hyaluronic acid versus placebo in patients with OA: overall analysis and analyses on studies with and without concomitant anti-OA medication allowed. *CI* confidence interval, *OA* osteoarthritis

Overall, there were significant increased odds of withdrawals due to AEs with IAHA (OR = 1.62, 95% CI 1.04--2.51; *I*^2^ = 10.0%) and increased but not statistically significant odds of withdrawals due to AEs in studies of IAHA without concomitant anti-OA treatment (OR = 1.80, 95% CI 0.99--3.26; *I*^2^ = 23.7%) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Forest plot displaying the results of the meta-analyses comparing withdrawals due to adverse events with IAHA versus placebo in patients with OA: overall analysis and analyses on studies with and without concomitant anti-OA medication allowed. *CI* confidence interval, *IAHA* intra-articular hyaluronic acid, *OA* osteoarthritis

Assessment of Publication Bias {#Sec15}
------------------------------

Funnel plot asymmetry was visually investigated for each of the primary or secondary outcomes assessed for IAHA compared with placebo. The Harbord's test was also performed, when sufficient data were available. Whatever the outcome considered, visual inspection of funnel plots and the Harbord's test for funnel plot asymmetry (when possible) showed that there was no evidence of publication bias. The funnel plot for "total AEs" is depicted in Fig. [8](#Fig8){ref-type="fig"}; all the other funnel plots are provided as Electronic Supplementary Material (ESM3).Fig. 8Assessment of publication bias: funnel plot using data for the meta-analysis comparing total adverse events with intra-articular hyaluronic acid versus placebo in patients with OA. Harbord's test: *p* = 0.26. *OA* osteoarthritis, *OR* odds ratio

GRADE Assessment of Findings {#Sec16}
----------------------------

We assessed the certainty of evidence for each primary or secondary outcome for IAHA compared with placebo, using the GRADE approach \[[@CR49]\]. Our findings were associated with "low" to "moderate" certainty of evidence, due to serious risk of bias issues (reporting bias and/or attrition bias) across the included studies. Additionally, we found large imprecisions with some overall effect estimates because of a low number of events (null events were reported in many of the included studies and for most of the outcomes). Table [3](#Tab3){ref-type="table"} summarizes the findings on quality assessment for all outcomes assessed in this meta-analysis, showing the overall analysis data. The certainty of the evidence was the same overall and with "studies without any concomitant anti-OA medication" for almost all the outcomes, apart from "severe adverse events" for which quality was graded as "low" (in contrast to "moderate", overall) (data not shown). When considering the studies with concomitant anti-OA medication, the certainty of the evidence for "nervous system disorders" was rather "low" (in contrast to "moderate" for the other groups), and was "moderate" for "vascular disorders" and "hypersensitivity reaction" (in contrast to "low" for the other groups) (data not shown). These differences in the quality of evidence were due to differences in imprecision around the estimates.Table 3Summary of safety findings for intra-articular hyaluronic acid (IAHA) compared to placebo in patients with osteoarthritisOrgan Class, *TRAEs* treatment-related adverse eventsOutcomesNo. of participants (studies), follow-upCertainty of the evidence (GRADE)Overall relative effect (95% CI)Anticipated absolute effectsRisk with placeboRisk difference with IAHAGastrointestinal adverse events1936 (11 RCTs)⊕⊕⊕◯\
MODERATE0.81 (0.52--1.27)87 per 100015 fewer per 1000\
(40 fewer to 21 more)Cardiac disorders2560 (13 RCTs)⊕⊕◯◯\
LOW^a,b^1.25 (0.36--4.41)3 per 10001 more per 1000\
(2 fewer to 11 more)Vascular disorders2560 (13 RCTs)⊕⊕◯◯\
LOW^a,b^1.70 (0.39--7.29)2 per 10002 more per 1000\
(1 fewer to 15 more)Respiratory, thoracic and mediastinal disorders2560 (13 RCTs)⊕⊕⊕◯\
MODERATE^a^1.21 (0.82--1.78)42 per 10008 more per 1000\
(7 fewer to 30 more)Nervous system disorders2089 (11 RCTs)⊕⊕⊕◯\
MODERATE^a^1.15 (0.77--1.70)54 per 10008 more per 1000\
(12 fewer to 35 more)Skin and subcutaneous tissue disorders1173 (8 RCTs)⊕⊕◯◯\
LOW^a,b^1.71 (0.52--5.63)18 per 100012 more per 1000\
(8 fewer to 74 more)Musculoskeletal and connective tissue disorders2962 (13 RCTs)⊕⊕⊕◯\
MODERATE^a^0.99 (0.71--1.39)101 per 10001 fewer per 1000\
(27 fewer to 34 more)Renal and urinary disorders2560 (13 RCTs)⊕⊕⊕◯\
MODERATE^a^0.54 (0.21--1.41)10 per 10004 fewer per 1000\
(8 fewer to 4 more)Infections and infestations2019 (11 RCTs)⊕⊕⊕◯\
MODERATE^a^0.61 (0.40--0.93)65 per 100024 fewer per 1000\
(38 fewer to 4 fewer)Hypersensitivity reaction2560 (13 RCTs)⊕⊕◯◯\
LOW^a,b^0.64 (0.05--7.94)15 per 10005 fewer per 1000\
(14 fewer to 94 more)Severe adverse events3232 (14 RCTs)⊕⊕⊕◯\
MODERATE^a^1.08 (0.50--2.31)16 per 10001 more per 1000\
(8 fewer to 20 more)Serious adverse events3956 (16 RCTs)⊕⊕⊕◯\
MODERATE^a^1.78 (1.21--2.63)22 per 100017 more per 1000\
(5 more to 34 more)Withdrawals due to adverse events3540 (15 RCTs)⊕⊕⊕◯\
MODERATE^a^1.62 (1.04--2.51)26 per 100015 more per 1000\
(1 more to 36 more)Any adverse event3476 (14 RCTs)⊕⊕⊕◯\
MODERATE^a^1.09 (0.90--1.31)487 per 100022 more per 1000\
(26 fewer to 67 more)GRADE working group grades of evidence: *High certainty*: we are very confident that the true effect lies close to that of the estimate of the effect; *Moderate certainty*: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; *Low certainty:* our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; *Very low certainty:* we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effectThe risk in the intervention group and its 95% CI are based on the assumed risk in the comparison group and the relative effect of the intervention and its 95% CI*CI* confidence interval, *OR* odds ratio, *RCT* randomized controlled trial^a^High risk of incomplete outcome data (attrition bias) and selective outcome reporting (reporting bias) found in many of the included studies. Full safety data were provided by authors of manuscripts for only 2 studies^b^Wide CI because of low number of events

Discussion {#Sec17}
==========

Overall this meta-analysis found no increased odds of total AEs with IAHA compared with placebo; this is particularly true for studies without concomitant anti-OA medication (OR = 1.19, 95% CI 0.92--1.54), but also for studies that allowed concomitant anti-OA medication. When considering only the studies which responded to our selection criteria, particularly the criteria related to the non-use of concomitant anti-OA medications during the trials, we found no statistically significant increased odds of SAEs with IAHA compared to placebo, even though there are more SAEs with IAHA (OR = 1.78, 95% CI 0.92--3.47).

However, we found significant increased odds of SAEs in the IAHA group versus placebo, overall and particularly in studies with concomitant OA treatment allowed (OR = 1.78, 95% CI 1.10--2.89). This compares with the findings of a meta-analysis from Rutjes et al., which found a 41% increased relative risk (RR) of SAEs (RR = 1.41, 95% CI 1.01--1.74) \[[@CR33]\]. In our analysis, the main studies leading to these results are the Jubb et al. 2003 study \[[@CR82]\], the Kwon et al. 2013 study \[[@CR83]\], and the Strand et al. 2012 study \[[@CR92]\], respectively counting for 33.29, 13.03, and 1.87% of the total weight of all studies. In the Jubb et al. 2003 study, the free use of analgesics and NSAIDs except indomethacin was permitted during the trial \[[@CR82]\]. In the Kwon et al. 2013 study, the usual regimen of pain medications could be maintained, but no additional treatment to the shoulder was allowed during the trial \[[@CR83]\]. In Strand et al. \[[@CR92]\] study, NSAIDs, herbal therapies, oral HA, glucosamine, chondroitin sulfate, minocycline and short-acting oral opiates were allowed during the trial. Oral NSAIDs are associated with an increased risk of SAEs \[[@CR94]\], and the increased odds of SAEs reported in these studies might be due to the concomitant use of NSAIDs or other medications. These results are, however, difficult to interpret due to the paucity in the reporting of safety data for IAHA.

Like the Rutjes meta-analysis \[[@CR33]\], our analysis includes data from the trial of Strand et al. of a cross-linked HA product (Gel-200) \[[@CR92]\]. While the trial found a similar rate of AEs between IAHA and saline placebo, eight cases of SAEs were reported in the Gel-200 group, all judged unrelated to study treatment, including five cancers diagnosed soon after treatment administration. The biological plausibility of a link between IAHA and the SAEs reported has been questioned in the literature \[[@CR95], [@CR96]\], and there is no pre-clinical data to suggest any carcinogenicity with Gel-200 \[[@CR92]\]. In contrast with our meta-analysis, which includes all types of HA, two meta-analyses of US-approved HA products have found no statistically significant differences between IAHA and IA placebo for any safety outcomes \[[@CR34], [@CR35]\].

We found a significant increase in odds of withdrawals due to AEs associated with IAHA overall (+ 62%; 95% CI 1.04--2.51), which was particularly high in studies of IAHA without concomitant anti-OA treatment (+ 80%) although this result did not reach significance (95% CI 0.99--3.26). This is in agreement with the Rutjes meta-analysis, which did not make any difference in the studies regarding to the use of concomitant anti-OA medications and also found an overall increased risk of dropouts due to AEs (RR = 1.33; 95% CI 1.01--1.74) \[[@CR33]\].

We observed a high rate of selective outcome reporting in the studies included in this meta-analysis; over 50% of studies did not adequately report safety data (Fig. [3](#Fig3){ref-type="fig"}a, b). Only two authors (Jorgensen et al. \[[@CR65]\]; van der Weegen et al. \[[@CR72]\]) shared full safety reports with us for the purpose of this meta-analysis, and no full safety report was obtained for any of the studies with concomitant anti-OA medications. This may have led to a very large underestimation of the odds of AEs associated with IAHA, because most of the studies included in the analyses did not report all treatment-emergent AEs in both the intervention and control groups \[[@CR73], [@CR82], [@CR89], [@CR92]\]. Consequently, assessing the certainty of evidence using the GRADE approach, we found "low" to "moderate" certainty with all the outcomes evaluated, none of the results being associated with a "high" certainty of evidence.

For SOC comparisons, in our analysis, no statistically significant difference was found between IAHA injections and placebo for all categories, with the exception of infections and infestations. Overall, in the IAHA treatment group, there was significant lower odds of infections and infestations compared with the placebo group (OR = 0.61, 95% CI 0.40--0.93). This was also the case in the group of studies without concomitant pharmacological OA treatment (OR = 0.49, 95% CI 0.27--0.89). This has significantly been reported by a single study (Jorgensen et al. \[[@CR65]\]), for which the author provided us with the full safety report and in which the main events reported were influenza, urinary tract infection, and pneumonia. This study counted for almost half (47.09%) of the weight of studies included in the overall analysis. A second study (with concomitant anti-OA medication) representing 49.84% of the overall studies weight also reported fewer infections in the IAHA group compared with placebo, but the difference in odds was not statistically significant (Jubb et al. \[[@CR82]\]). A few in vitro studies suggest an anti-microbial effect of HA at levels of 1 mg/mL and over \[[@CR97], [@CR98]\]. These levels are unlikely to be achieved systemically following IA injection. However, if the results provided by the two RCTs demonstrating a lower rate of infections with IAHA versus placebo are not due to chance, they could suggest a systemic exposure of HA administered by IA injection. Further data are therefore needed to clarify this.

Given our findings overall, further investigation into the safety of IAHA is warranted. There are already a large number of studies that have assessed the efficacy and safety of IAHA in OA; the main issue is not therefore the lack of studies, but the lack of transparency in the reporting of IAHA safety data. Particularly, it would be interesting if the pharmaceutical companies could cooperate in future meta-analyses by giving access to full safety reports from the studies. Additionally, long-term safety studies are warranted as IAHA is often given as repeated courses of three to five injections; in fact, for most of the studies included in this systematic review, the follow-up durations varied from 8 to 26 weeks (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Multiple courses of IAHA are shown to be safe over 6--18 months from a post-marketing registry of one HA product (Supartz), with an overall AE rate of 0.008 (95% CI 0.001--0.055) \[[@CR37]\]. The majority of people who reported an AE did so in the first injection series, of which 85% were injection site reactions. Conversely, an increased frequency of acute local reactions has been reported with multiple cycles of IAHA \[[@CR99]\], while one review reports that the safety remains unchanged with multiple courses of treatment \[[@CR100]\]. Additionally, it has been reported that, in comparison with other pharmacological treatments for OA, IAHA appears to be associated with fewer systemic AEs than paracetamol or NSAIDs, but more local reactions, and a lower rate of withdrawals due to AEs \[[@CR16], [@CR17]\]. However, all this evidence deserves further investigation; transparency in the reporting of harms collected during clinical trials on IAHA will assist significantly in clarifying the safety profile of IAHA, for which the onus is on pharmaceutical companies developing HA for patients with OA.

Strengths {#Sec18}
---------

Only RCTs versus placebo were included, and hence, the real effect is not underestimated. Many SOCs were investigated; not only "total AEs", "SAEs" or "skin AEs", as reported in many previous meta-analyses. To avoid double counting of AEs, for each SOC, we considered the number of patients who experienced at least once any related AE. For total AEs (any AEs), we considered the number of patients who experienced, at least once, any AE during the study.

Limitations {#Sec300}
===========

Many studies identified that met the inclusion criteria did not provide AE data suitable for inclusion in the meta-analysis and the authors/sponsors did not provide us with the full safety data. As a consequence, subgroup analyses were not possible, which would have helped to explore any subgroup differences in the occurrence of SAEs with the studies included in the parallel post hoc meta-analysis (e.g. analyses by HA subtypes).

Conclusions {#Sec400}
===========

Paucity in the reporting of AEs does not allow for a definitive conclusion regarding the safety profile of IAHA in OA. Based on the available data regarding studies without concomitant anti-OA medications, IAHA seems not to be associated with any safety issue in the management of OA; however, the certainty of this evidence was graded between "low" and "moderate". The SAEs found in some other meta-analyses as well as in our parallel post hoc analysis might be due to the allowance for concomitant use of oral NSAIDs during some trials or to other factors, but this deserves further investigation. Overall, further investigation on the safety of IAHA is warranted, in particular, greater contribution from pharmaceutical companies in providing full safety reports for future meta-analyses. Authors of manuscripts on future trials on IAHA are also encouraged to report harms collected during these trials in a transparent way. Further studies are also required to determine the long-term safety of IAHA.
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